HSK44459
/ Haisco
- LARVOL DELTA
Home
Next
Prev
1 to 13
Of
13
Go to page
1
July 14, 2026
Late Breaking Abstract - A Phase II Clinical Study of HSK44459 in Patients with Idiopathic Pulmonary Fibrosis
(ERS 2026)
- P2 | "HSK44459 demonstrated excellent safety and tolerability. HSK44459 8 mg and 12 mg, with or without background antifibrotic therapy, effectively slowed lung function decline in patients with IPF, with HSK44459 12 mg showing potential for greater efficacy."
Clinical • Late-breaking abstract • P2 data • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
June 04, 2026
Trial of HSK44459 Cream for the Management Plaque Psoriasis
(clinicaltrials.gov)
- P1/2 | N=180 | Active, not recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P1/2 trial • Dermatology • Immunology • Psoriasis
April 14, 2026
HSK44459-201: Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis
(clinicaltrials.gov)
- P2 | N=186 | Completed | Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Completed | N=120 ➔ 186 | Trial completion date: Jul 2026 ➔ Mar 2026
Enrollment change • Trial completion • Trial completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
April 10, 2026
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis
(clinicaltrials.gov)
- P3 | N=420 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P3 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
April 01, 2026
PPF: Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis
(clinicaltrials.gov)
- P3 | N=378 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P3 trial • Immunology • Pulmonary Disease • Respiratory Diseases
January 03, 2026
A Study for HSK44459 in Participants With Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=150 | Active, not recruiting | Sponsor: Xizang Haisco Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting
Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
June 12, 2025
First-in-Human Phase I Trial: the Safety, Tolerability, and Pharmacokinetics of HSK44459 in Healthy Subjects
(ERS 2025)
- "HSK44459 was safe and well tolerated in healthy subjects. The encouraging PK and PD profiles support its further development."
Clinical • First-in-human • P1 data • PK/PD data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
September 03, 2025
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
(clinicaltrials.gov)
- P2 | N=150 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P2 trial • Dermatology • Immunology • Psoriasis
July 17, 2025
A Long-term Study of HSK44459 Tablets in Participants With Bechet's Disease
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P2 trial
June 13, 2025
Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
May 30, 2025
A Study for HSK44459 in Participants With Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=150 | Recruiting | Sponsor: Xizang Haisco Pharmaceutical Co., Ltd
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
March 31, 2025
Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P2 trial • Immunology • Rare Diseases
March 12, 2025
Clinical trial of HSK44459, a new drug of Hiseco's subsidiary, was approved [Google translation]
(Eastmoney.com)
- "March 12, Haisike(002653) announced that its subsidiary Shanghai Hisuno Pharmaceutical Technology Co., Ltd. recently obtained the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration, approving its new drug HSK44459 tablets for clinical trials of psoriasis and atopic dermatitis."
New trial • Atopic Dermatitis • Psoriasis
1 to 13
Of
13
Go to page
1